The Institute for Clinical and Economic Review (ICER) released a report on Monday assessing the clinical effectiveness and ...

Pharma with 4,314 puts trading, or 4x expected. Most active are Mar-25 38.5 puts and Apr-25 37 puts, with total ...

An international collaboration of researchers, sponsored by GSK and working on behalf of the ANCHOR-1 and ANCHOR-2 trial ...

London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review the Biologics License ...

US FDA accepts for review GSK’s BLA for depemokimab for asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps: London, UK Tuesday, March 4, 2025, 09:0 ...

GSK plc (GSK) has announced on Monday that the FDA has accepted its Biologics License Application (BLA) for depemokimab for regulatory review in two indications.The proposed ...

In the SWIFT and ANCHOR trials, depemokimab demonstrated statistically significant reductions in nasal polyp size, ...

The US Food and Drug Administration (FDA) has accepted for review GSK’s Biologics License Application for depemokimab.

FDA reviews GSK depemokimab for asthma and CRSwNP, with a decision expected by December 2025. Phase 3 data shows improvements ...

Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...

GSK (GSK) announced the US Food and Drug Administration, FDA, has accepted for review the Biologics License Application, BLA, for the use of ...

Secondary endpoint analyses from the trials showed 'significant improvements' in patients treated with the antibody.